News |

ICYMI, this week we had stories about dermatologic disparities among veterans and LGBTQIA+ patients, pediatric melanoma, a European approval for hidradenitis suppurativa, and more.

Researchers examined the disease while going beyond current diagnostic tools.

The World Health Organization shared its enthusiasm for the “appropriate” use of these technologies. However, they are calling for caution to be exercised to protect and promote human well-being, safety, and autonomy and preserve public health.

Scientists have found a new therapy for the severe inflammatory skin disorder.

The approval makes the drug Europe’s first and only IL-17A inhibitor approved for the condition.

As Pride Month begins, the Dermatology Times® team wants to uplift LGBTQIA+ clinicians, patients, and topics in dermatology.

Apremilast is being examined for the treatment of psoriatic arthritis.

As senior director, Del Rosso is looking forward to presenting numerous sessions and welcoming attendees to Orlando.

A public exhibition spotlighting individuals with birthmarks improved participants’ wellbeing and sense of self image.

The phase 3b trial showed improvements to minimal disease activity in adults with the condition.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of May.

In this week’s Pointers with Portela, the 208SkinDoc explains his recommendations for effective products to buy to start a skin care routine.

Cameron Dermatology, which just opened in NYC, will address both medical and cosmetic issues.

In part 4 of this Frontline Forum series, John M. Strasswimmer, MD, PhD; Andrew H. Weinstein, MD; Neal Bhatia, MD; Laura Ferris, MD; and Aaron S. Farberg, MD, discuss solutions for managing and treating patients with basal cell carcinoma.

Researchers conducted a systematic review of pediatric melanoma.

Cryoanesthesia was safe and reduced pain in patients receiving intralesional triamcinolone steroid injections.

This week's edition of the Mainstream Patient features stories about 8 Black-owned holistic beauty brands, tear trough filler for under-eye bags, dermatologist-approved SPF-containing moisturizers, and more.

Click here to answer this week's poll.

Learn more about the in-depth topics covered in the May 2023 issue of Dermatology Times®.

In this month’s Legal Eagle column, we delve into cases involving informed consent.

This Memorial Day, the Dermatology Times® team is taking the time to spotlight dermatologic disparities and concerns among veterans and active members of the military.

Learn from a panel of sun protection experts on how to effectively prepare your patients for the summer sun.

ICYMI, this week we had stories about more adalimumab biosimilars, brepocitinib for psoriatic arthritis, sunscreen screenings for veterans, and more.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Coastal regions require environmentally-protective sun protection measures and best practices.

In this month’s Finance & Practice Management column, we illustrate the importance of developing and maintaining a budget for physicians at all stages of their careers.

This week's edition of the Mainstream Patient features stories about facial balancing, eyelid surgery 101, dermatologist-recommended sunscreen sticks, and more.

The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.

Yuflyma will be available to US patients in July 2023.

The JAK inhibitor demonstrated promising efficacy and safety.